読み込み中
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.
前日終値
$14.67
+$0.47 · +3.31%
日中の時刻はETです。市場データは遅延する場合があります。
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.
日中レンジ
現在 $14.67
52週レンジ
現在 $14.67
日中の時刻はETです。市場データは遅延する場合があります。
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.
日中レンジ
現在 $14.67
52週レンジ
現在 $14.67
| 指標（USD） | 2025年度 |
|---|---|
| 研究開発 | 1.53億 USD |
| 販売・一般管理 | 4875万 USD |
| 営業費用 | 2.02億 USD |
| 受取利息 | 685万 USD |
| 減価償却費と償却費 | 584.7万 USD |
| 営業利益 | −2.02億 USD |
| 純利益 | −1.92億 USD |
会社概要が更新されました 2026年10月12日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$38.50
上昇余地（162.44%）この株式へのエクスポージャーを報告している上場投資信託です。
iShares Russell 2000 ETFIWM1063.09万0.01%787.4億 USD0.19%$278.94+0.49%
iShares Russell 2000 Growth ETFIWO222.75万0.02%139.17億 USD0.24%$356.78+0.94%
Schwab U.S. Small-Cap ETFSCHA194.37万0.01%218.24億 USD0.03%$32.79+0.40%
Vanguard Morningstar Total Stock Market ETFVTI190.56万0.00%2.3兆 USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF67.04万0.00%954億 USD0.05%$235+0.80%
Goldman Sachs Small Cap Equity ETFGSC53.4万0.19%2.77億 USD0.80%$62.30+0.70%
Vanguard Russell 2000 ETFVTWO31.97万0.00%180億 USD0.06%$112.66+0.50%
Fidelity Nasdaq Composite Index ETFONEQ29.73万—109.4億 USD0.21%$107.81+0.63%iShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFGoldman Sachs Small Cap Equity ETFGSCVanguard Russell 2000 ETFVTWOFidelity Nasdaq Composite Index ETFONEQAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
